This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Thursday's Health Winners & Losers

Noven shares rose $1.24, or 9.2%, to $14.75.

Wednesday after close, Somaxon Pharmaceuticals (SOMX) reported a net loss of $5.7 million, or 31 cents a share, vs. $9.8 million, or 55 cents a share, for the year-ago quarter. Analysts were expecting a loss closer to 39 cents a share for the quarter, and JP Morgan upgraded the stock to neutral from underweight on Thursday. Shares garnered 89 cents, or 15.5%, to $6.65.

Less fortunate Thursday was Abraxis BioScience (ABBI), which reported adjusted third-quarter earnings of $23.1 million, or 15 cents a share, in the recent quarter, compared to $16.7 million, or 10 cents a share, in the year-ago period. And the company reported revenue of $241 million, vs. $203.1 million in the 2006 quarter, falling shy of estimates of analysts surveyed by Thomson Financial who expected 22 cents a share, on revenue of $253.9 million. Shares fell $2.29, or 9.5%, to $21.93.

Also, Corcept (CORT) gave up 49 cents, or 15.2%, to $2.75. The company reported a third-quarter loss of $3.4 million, or 9 cents a share, vs. a loss of $6.4 million, or 28 cents a share, in the year-ago period. The consensus target was for a loss of 9 cents a share.

And hitting a new 52-week low, BioCryst (BCRX) aired its results as well. The company reported revenue of $20.5 million vs. $1.8 million in the year-ago quarter, and a net loss of $11 million, or 32 cents a share, compared to a loss of $15.6 million, or 53 cents a share, in the year-ago quarter. The consensus target was a loss of 28 cents a share on revenue of $10.51 million. Shares declined 72 cents, or 9.4%, to $6.95.

2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs